Medicity Research Laboratory, University of Turku, Turku, Finland; Turku Doctoral Programme of Biomedical Sciences, University of Turku, Turku, Finland.
Laryngoscope. 2013 Oct;123(10):2435-41. doi: 10.1002/lary.23888. Epub 2013 Aug 5.
OBJECTIVES/HYPOTHESIS: Early-stage oral squamous cell carcinoma (OSCC) treatment is based on anatomic location, clinical TNM staging, and histological grade. It is a heterogeneous disease group. Classification of patients with OSCC by immunohistochemical analysis of established oncoproteins and evaluate disease course was our primary objective. Characterization of stage I OSCC patients in Southwest Finland was our secondary objective.
Immunohistochemical analysis of tumor specimens and retrospective analysis of patient data of the patient treated in Turku University Hospital for T1N0M0 OSCC during the years 2000-2004.
Paraffin-embedded tumor specimens from 35 OSCC patients were collected and analyzed for HIF-1α, CD44, p16, Ki67, and podoplanin by immunohistochemistry and correlated with clinical findings.
Tumoral CD44 and HIF1-α expression levels, in combination, predicted 5-year disease-free survival. Reduced expression of CD44 and elevated expression of HIF1-α is associated with the lowest probability of disease-free survival compared to the population as a whole (P < .001 in Kaplan-Meier analysis). Patients with grade I tumors demonstrated improved disease-specific survival compared to those with grade II tumors (P = .027). No association was seen between p16 expression, Ki67 labeling index, or podoplanin expression and prognosis in our 35 specimens.
HIF-1α and CD44 immunohistochemical detection could potentially serve as a prognostic tool in therapy selection for early-stage OSCC.
2b.
目的/假设：早期口腔鳞状细胞癌（OSCC）的治疗基于解剖位置、临床 TNM 分期和组织学分级。它是一组异质性疾病。我们的主要目标是通过对既定癌蛋白进行免疫组织化学分析对 OSCC 患者进行分类，并评估疾病过程。我们的次要目标是对芬兰西南部的 I 期 OSCC 患者进行特征描述。
对 2000-2004 年在图尔库大学医院接受 T1N0M0 OSCC 治疗的患者的肿瘤标本进行免疫组织化学分析，并对患者数据进行回顾性分析。
收集 35 例 OSCC 患者的石蜡包埋肿瘤标本，采用免疫组织化学方法分析 HIF-1α、CD44、p16、Ki67 和 podoplanin，并与临床发现相关联。
肿瘤 CD44 和 HIF1-α 的表达水平相结合可预测 5 年无病生存率。与总体人群相比，CD44 表达降低和 HIF1-α 表达升高与无病生存率最低相关（Kaplan-Meier 分析中 P <.001）。与 II 级肿瘤相比，I 级肿瘤患者的疾病特异性生存率更高（P =.027）。在我们的 35 个标本中，p16 表达、Ki67 标记指数或 podoplanin 表达与预后均无关联。
HIF-1α 和 CD44 的免疫组织化学检测可能成为早期 OSCC 治疗中选择治疗方案的预后工具。
2b。
